Logout
If you want to log out click in LogOut
The RAS-MAPK signaling pathway is a highly conserved intracellular cascade that transduces signals from activated receptor tyrosine kinases (RTKs) to the nucleus, regulating gene expression programs that control proliferation, differentiation, survival, and migration.
This pathway is initiated at the plasma membrane following ligand binding to RTKs, leading to recruitment of adaptor proteins such as GRB2 and SOS1. SOS1 promotes GDP–GTP exchange on RAS proteins (KRAS, NRAS, HRAS), triggering activation of RAF kinases (ARAF, BRAF, CRAF). RAF subsequently phosphorylates MEK1/2 (MAP2K1/2), which activate ERK1/2 (MAPK3/1).
Activated ERK translocates to the nucleus and modulates transcription factors including ELK1, MYC, FOS, and JUN, reshaping gene expression to drive cell-cycle progression and adaptive responses.
Under physiological conditions, the RAS-MAPK cascade ensures controlled tissue growth and regeneration. Under oncogenic stress, sustained activation promotes uncontrolled proliferation and resistance to apoptosis.
RAS-MAPK signaling pathway activity can be efficiently assessed through transcriptional profiling of upstream regulators, ERK-responsive genes, and proliferation-associated targets, allowing discrimination between physiological signaling and oncogenic activation states.
RAS-MAPK signaling pathway biomarker list
View the genes included in our RAS-MAPK-related qPCR arrays.
Ligand binding to receptor tyrosine kinases induces receptor dimerization and autophosphorylation. These phosphotyrosine residues serve as docking sites for adaptor proteins such as SHC and GRB2.
GRB2 recruits SOS1, a guanine nucleotide exchange factor that catalyzes GDP-GTP exchange on RAS. GTP-bound RAS undergoes conformational activation and interacts with RAF kinases at the plasma membrane.
RAS activity is tightly regulated by GTPase-activating proteins (GAPs), which restore the inactive GDP-bound state, ensuring signaling fidelity.
Activated RAF kinases phosphorylate MEK1/2, which in turn phosphorylate ERK1/2 at conserved threonine and tyrosine residues.
Phosphorylated ERK translocates to the nucleus via interaction with importins and nuclear pore complexes. Once inside, ERK phosphorylates transcription factors including:
These transcriptional events regulate genes involved in:
Transient activation promotes adaptive proliferation. Sustained activation under pathological conditions drives oncogenic transformation.
The RAS-MAPK signaling pathway operates within a broader signaling network and exhibits extensive crosstalk with:
In the tumor microenvironment, this crosstalk shapes proliferation, immune evasion, angiogenesis, and resistance to targeted therapies.
Understanding these interactions is essential for accurate pathway biomarker interpretation.
Cancer
The RAS-MAPK signaling pathway is one of the most frequently dysregulated cascades in oncology.
Common alterations include:
Persistent ERK activation drives uncontrolled proliferation, angiogenesis, and therapy resistance.
RASopathies
Germline mutations affecting RAS-MAPK components underlie developmental disorders collectively termed RASopathies, including:
These disorders reflect aberrant developmental signaling and altered differentiation programs.
Neurological and Inflammatory Disorders
Emerging evidence links dysregulated RAS-MAPK signaling to:
Under chronic inflammatory stress, ERK activation reshapes immune and tissue remodeling programs.
Given its central role in tumorigenesis, the RAS-MAPK pathway has become a primary therapeutic target.
Approved and investigational strategies include:
However, resistance mechanisms frequently emerge through pathway reactivation or compensatory signaling.
Accurate transcriptional profiling of pathway activity is therefore critical for translational research and biomarker-guided patient stratification.
Investigating proliferative signaling requires reproducible and standardized gene expression analysis.
AnyGenes® provides pathway-focused qPCR arrays designed to:
In translational research settings, standardized profiling supports consistent interpretation across experimental models and therapeutic studies.
The RAS-MAPK SignArrays® panel includes genes related to:
Species available:
Custom pathway panels can be designed to address specific oncogenic hypotheses or translational objectives.
From targeted signaling interrogation to global pathway activation profiling, transcriptional signatures enable precise monitoring of RAS-MAPK signaling dynamics.
Scientific data is only as powerful as the analysis behind it.
AnyGenes® provides a dedicated data analysis tool specifically developed for SignArrays® pathway panels.
What does it allow you to do?
Developed on Excel (compatible with 2007+), the software is user-friendly and requires no advanced bioinformatics skills.
Customize your own signaling pathways (SignArrays®) with the factors of your choice!
Simply download and complete our Personalized SignArrays® information file
and send it at
[email protected]
to initiate your project.
The RAS-MAPK signaling pathway is a kinase cascade that transduces signals from receptor tyrosine kinases to ERK-mediated transcriptional programs controlling proliferation and survival.
It follows a RTK → RAS → RAF → MEK → ERK cascade, culminating in nuclear activation of transcription factors regulating cell-cycle genes.
Oncogenic mutations in KRAS, BRAF, or MEK lead to sustained ERK activation, driving uncontrolled proliferation and therapeutic resistance.
Key components include KRAS, NRAS, HRAS, BRAF, RAF1, MAP2K1/2, MAPK1/3, and ERK-responsive transcription factors.
Pathway activity can be assessed through transcriptional profiling of upstream regulators and ERK downstream targets using pathway-focused qPCR arrays.
| Signaling Pathways | Product ref | Informations |
|---|---|---|
RAS-MAPK Signaling Pathway | RAS1H1 |
| Signaling Pathways | Product ref | Informations |
|---|---|---|
RAS-MAPK Signaling Pathway | ******* |
Biomarker list in progress. |
| Signaling Pathways | Product ref | Informations |
|---|---|---|
RAS-MAPK Signaling Pathway | ******* |
Biomarker list in progress. |
| Signaling Pathways | Product ref | Informations |
|---|---|---|
RAS-MAPK Signaling Pathway | ******* |
Biomarker list in progress. |
Looking for more answers? Visit our Help & FAQ section to find detailed informations about our products, services, and technical support.
1. Bahar ME, Kim HJ, Kim DR. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target Ther. (2023)18;8(1):455.
2. Pudewell S, et al. Accessory proteins of the RAS-MAPK pathway: moving from the side line to the front line. Commun Biol. (2021)8;4(1):696.
3. Dillon M, et al. Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers. Cancers (Basel). (2021)10;13(20):5059.
4. Santarpia L, Lippman SM, El-Naggar AK. Targeting the Mitogen-Activated Protein Kinase RAS-RAF Signaling Pathway in Cancer Therapy. Expert Opin Ther Targets. (2012);16(1):103-19.